CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,110,053 | -15.5% | 76,674 | +4.2% | 0.00% | -33.3% |
| Q2 2023 | $2,495,653 | +93721.5% | 73,553 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $2,660 | -17.0% | 73,924 | +2.8% | 0.00% | -25.0% |
| Q4 2022 | $3,205 | -99.8% | 71,908 | +2.2% | 0.00% | +33.3% |
| Q3 2022 | $1,978,000 | +13.0% | 70,375 | +8.3% | 0.00% | 0.0% |
| Q2 2022 | $1,751,000 | -1.6% | 64,958 | +24.4% | 0.00% | +50.0% |
| Q1 2022 | $1,779,000 | -7.6% | 52,219 | +4.8% | 0.00% | 0.0% |
| Q4 2021 | $1,925,000 | -27.6% | 49,823 | +1.1% | 0.00% | -50.0% |
| Q3 2021 | $2,660,000 | +94.7% | 49,265 | +20.6% | 0.00% | +100.0% |
| Q2 2021 | $1,366,000 | – | 40,835 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |